ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AMRN Amarin Corp PLC

1.19
0.00 (0.00%)
Pre Market
Last Updated: 04:38:06
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Amarin Corp PLC AMRN NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 1.19 04:38:06
Open Price Low Price High Price Close Price Previous Close
1.19
more quote information »

Recent News

Date Time Source Heading
2/15/202407:00GLOBEAmarin to Report Fourth Quarter and Full Year 2023 Financial..
2/12/202407:00EDGAR2Form PRE 14A - Other preliminary proxy statements
2/09/202415:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/09/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/09/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/02/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/02/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/02/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/26/202406:00EDGAR2Form 8-K - Current report
1/24/202415:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/22/202406:30GLOBEAmarin Chairman & CEO Issue Letter to Shareholders
1/12/202416:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/12/202416:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/12/202416:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/10/202406:00EDGAR2Form 8-K - Current report
1/10/202406:00GLOBEAmarin Provides Preliminary Fourth Quarter 2023 Selected..
1/08/202417:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/08/202417:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/02/202415:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/02/202415:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/14/202317:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202315:20EDGAR2Form 144 - Report of proposed sale of securities
12/11/202307:00GLOBEAmarin to Present at the 42nd Annual J.P. Morgan Healthcare..
12/05/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/05/202306:30EDGAR2Form SC 13D/A - General statement of acquisition of..
11/12/202308:00GLOBENew REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl)..
11/03/202315:30EDGAR2Form 8-K - Current report
11/01/202306:05EDGAR2Form 8-K - Current report
11/01/202306:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/01/202306:00GLOBEAmarin Reports Third Quarter 2023 Financial Results
10/31/202315:05EDGAR2Form 8-K - Current report
10/31/202311:00GLOBEAmarin Appoints Jonathan Provoost Executive Vice President,..
10/26/202307:00GLOBELatest Research Evaluating VASCEPA®/VAZKEPA® (icosapent..
10/19/202307:00GLOBE Amarin to Report Third Quarter 2023 Financial Results and..
9/12/202307:00GLOBEAmarin to Present at the 2023 Cantor Global Healthcare..
9/05/202315:15EDGAR2Form SC 13D/A - General statement of acquisition of..
8/16/202318:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/15/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
8/09/202315:05GLOBEAmarin Provides Pricing & Reimbursement Updates for VAZKEPA..
8/08/202306:00GLOBEAmarin And Neopharm Announce Exclusive Commercialization..
8/07/202306:00GLOBEScottish Medicines Consortium Accepts VAZKEPA® (icosapent..
8/02/202316:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/02/202316:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/02/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/02/202307:39EDGAR2Form S-8 - Securities to be offered to employees in employee..
8/02/202307:34EDGAR2Form S-3 - Registration statement under Securities Act of..
8/02/202306:11GLOBEAmarin Reports Second Quarter 2023 Financial Results
8/02/202306:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/02/202306:01EDGAR2Form 8-K - Current report
7/31/202307:00GLOBEAmarin and Lotus Pharmaceuticals Announce Exclusive..

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com